Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

Targeting drug-resistant mutations in ALK

Nature Cancer volume 3, pages 659–661 (2022)Cite this article

Subjects

Therapy resistance limits the clinical success of tyrosine kinase inhibitors (TKIs) in ALK-positive non-small cell lung cancer. A study now proposes a framework to identify compound resistance mutations to the lorlatinib TKI and provides structure-based drug design approaches to overcome resistance mediated by ALK(G1202R) or ALK(I1171N/S/T).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mechanism of ALK compound mutations and inhibition by LA9 and LA7.

References

  1. Cohen, P. et al. Nat. Rev. Drug Discov. 20, 551–569 (2021).

    Article  CAS  Google Scholar 

  2. Settleman, J. Curr. Biol. 22, R43–R44 (2012).

    Article  CAS  Google Scholar 

  3. Shah, N. P. et al. Cancer Cell 2, 117–125 (2002).

    Article  CAS  Google Scholar 

  4. Yun, C. H. et al. Proc. Natl. Acad. Sci. USA 105, 2070–2075 (2008).

    Article  CAS  Google Scholar 

  5. O’Hare, T. et al. Cancer Cell 16, 401–412 (2009).

    Article  Google Scholar 

  6. Cross, D. A. et al. Cancer Discov. 4, 1046–1061 (2014).

    Article  CAS  Google Scholar 

  7. Gainor, J. F. et al. Cancer Discov. 6, 1118–1133 (2016).

    Article  CAS  Google Scholar 

  8. Yoda, S. et al. Cancer Discov. 8, 714–729 (2018).

    Article  CAS  Google Scholar 

  9. Shiba-Ishii, A. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00399-6 (2022).

  10. Fitzmaurice, C. et al. JAMA Oncol. 3, 524–548 (2017).

    Article  Google Scholar 

  11. Pikor, L. A. et al. Lung Cancer 82, 179–189 (2013).

    Article  Google Scholar 

  12. Sabir, S. R. et al. Cancers (Basel) 9, 118 (2017).

    Article  Google Scholar 

  13. Choo, J. R. & Soo, R. A. Expert Rev. Anticancer Ther. 20, 233–240 (2020).

    Article  CAS  Google Scholar 

  14. Bresler, S. C. et al. Cancer Cell 26, 682–694 (2014).

    Article  CAS  Google Scholar 

  15. Dagogo-Jack, I. & Shaw, A. T. Ann. Oncol. 27, iii42–iii50 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncological Sciences, The Tisch Cancer Institute, Mount Sinai Centre for Therapeutic Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Liu He & Arvin C. Dar

  2. Department of Pharmacological Sciences, The Tisch Cancer Institute, Mount Sinai Centre for Therapeutic Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Liu He & Arvin C. Dar

Authors
  1. Liu He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arvin C. Dar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arvin C. Dar.

Ethics declarations

Competing interests

A.C.D. is a founder, shareholder, consultant and advisory board member of Nested Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, L., Dar, A.C. Targeting drug-resistant mutations in ALK. Nat Cancer 3, 659–661 (2022). https://doi.org/10.1038/s43018-022-00390-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00390-1

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer